Adaptimmune Therapeutics PLC

NASDAQ:ADAPUnited States

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Contact Information

Headquarters

60 Jubilee Avenue, Milton ParkABINGDON, United Kingdom OX14 4RX

Phone

123-543-0000

Fax

---

Executives

Non-Executive Independent Chairman of the Board

David Mott

Chief Executive Officer, Director

Adrian Rawcliffe

Chief Financial Officer

Gavin Wood

Chief Operating Officer

William Bertrand

Chief Scientific Officer

Joanna Brewer